Sloan-Kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Rena May

David A Scheinberg

Michael R McDevitt

Javier Pinilla-Ibarz

Christophe Antczak

Debjit Chattopadhyay

Jon T Njardarson

Mark Reid Phillips

Mark Reid Philips

Jón T Njardarson

David Scheinberg

WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME

The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

Single wall nanotube constructs and uses thereof

This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

WT1 HLA class II-binding peptides and compositions and methods comprising same

This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.

Immunogenic WT-1 peptides and methods of use thereof

This invention provides mutated WT1 peptides SGQAYMFPNAPYLPSCLES (SEQ ID No:41) and QAYMFPNAPYLPSCL (SEQ ID No:42), immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.

WT1 HLA class II&#x2014;binding peptides and compositions and methods comprising same

The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.

Growing community of inventors

Baltimore, MD, United States of America

Rena May